Clinical Trials Logo

Dry Eye clinical trials

View clinical trials related to Dry Eye.

Filter by:

NCT ID: NCT06329687 Active, not recruiting - Dry Eye Clinical Trials

A Phase 4 Study Evaluating the Safety of the Nasal Pump

Start date: February 21, 2024
Phase: Phase 4
Study type: Interventional

The objective of this study is to determine the safety of the Tyrvaya nasal pump.

NCT ID: NCT06324890 Recruiting - Dry Eye Clinical Trials

PET-CT Imaging Features of Meibomian Glands

Start date: January 31, 2024
Phase:
Study type: Observational

Analysis the results of Dry eye analysis results and PET-CT imaging comprehensively

NCT ID: NCT06309953 Recruiting - Dry Eye Clinical Trials

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Start date: February 28, 2024
Phase: Phase 4
Study type: Interventional

An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

NCT ID: NCT06296966 Recruiting - Dry Eye Clinical Trials

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Start date: February 29, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

NCT ID: NCT06294015 Not yet recruiting - Glaucoma Clinical Trials

Efficacy of 20% Autologous Serum Drops in the Treatment of Corneal Epitheliopathy Associated With Antihypertensive Glaucoma Drops.

Start date: March 2024
Phase: Phase 4
Study type: Interventional

Introduction: Glaucoma is the second leading cause of blindness globally. Most anti-hypertensive drops contain preservatives harmful to the corneal epithelium, with up to 78% of treated patients reporting dry eye symptoms. Autologous serum eye drops (ASED), contains essential growth factors and nutrients which may promote corneal and conjunctival integrity, offering benefits over traditional treatments. This study investigates the efficacy of 20% ASED over placebo in the treatment of corneal epitheliopathies in patients with glaucoma treated with antihypertensive drops. Methods: The present study is a triple-blinded, randomized controlled trial that anticipates to enroll 25 patients (50 eyes) with bilateral corneal epitheliopathy secondary to antihypertensive glaucoma treatments. Patients will receive autologous serum eye drops in one eye and placebo in the contralateral eye for two months, in addition to standard artificial tears treatment. The primary outcome is the comparison of National Eye Institute (NEI) scores between autologous serum drops and placebo-treated eyes at two months. Secondary outcomes include Schirmer's test scores, visual acuity, tear break-up time (TBUT), Ocular Surface Disease Index (OSDI) scores, intraocular pressure, and complication rates. The study aims to analyze the effectiveness of autologous serum eye drops in treating corneal epitheliopathies in glaucoma patients, potentially offering a new therapeutic avenue.

NCT ID: NCT06287879 Recruiting - Dry Eye Clinical Trials

Function and Morphological Characteristics of Meibomian Gland in Patients With Renal Anemia

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Renal anemia refers to anemia in which the absolute or relative production of erythropoietin (EPO) is insufficient due to various kidney diseases, and uremic toxins affect erythropoietin production and its lifespan. Common treatment drugs for renal anemia include erythropoietin EPO and Roxadustat (FG-4592). Medical history information was collected from patients with renal anemia who visited the ophthalmology department with dry eye symptoms. This study will help to determine the function and morphological characteristics of meibomian gland in patients with renal anemia

NCT ID: NCT06271005 Not yet recruiting - Dry Eye Clinical Trials

Neurological Dry Eye Study Stimulating Both Lacrimal and Vagus Nerves

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This is a study on neurological dry eye disease, focusing on a patented over-the-counter supplement supporting tear production neurologically, including the lacrimal and vagus nerves.

NCT ID: NCT06269237 Not yet recruiting - Dry Eye Clinical Trials

Point of Care Test of LTA Level in Tear Fluid, Measured With a POCT Test, in DE Patients Following IPL Treatment

Start date: February 22, 2024
Phase: N/A
Study type: Interventional

To quantify and compare tear levels of Intense pulsed light (IPL) and traditional dry eye clinical tests in dry eye patients before and after Intense pulsed light (IPL) treatment.

NCT ID: NCT06245421 Recruiting - Dry Eye Clinical Trials

Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness

Start date: March 7, 2024
Phase: N/A
Study type: Interventional

This study is a multicentric, comparative, randomized, investigator-blinded, parallel group study to demonstrate the non-inferiority of DM934 in comparison with Théalose in terms of cornea and conjunctiva staining (Oxford score) on patients with moderate to severe ocular dryness, after 35 days of treatment

NCT ID: NCT06219577 Recruiting - Dry Eye Clinical Trials

Subjective and Objective Performance of Systane Complete Multi-Dose PF Versus Walgreen's Lubricant Balance

Start date: January 18, 2024
Phase: Phase 4
Study type: Interventional

Single site, prospective, double-masked, randomized-controlled, two-arm study of the dry eye symptoms as well as corneal and conjunctival staining in subjects using 2 different eyedrops. Subjects will be assessed at a screening visit, and 2 follow-up visits. Clinical evaluations will include patient questionnaire, tear-breakup time, and slit lamp exam.